These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Molecular biological assessment methods and understanding the course of the HIV infection. Katzenstein TL APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050 [TBL] [Abstract][Full Text] [Related]
4. Update on HIV resistance and resistance testing. Sebastian J; Faruki H Med Res Rev; 2004 Jan; 24(1):115-25. PubMed ID: 14595674 [TBL] [Abstract][Full Text] [Related]
5. New antivirals and drug resistance. Colman PM Annu Rev Biochem; 2009; 78():95-118. PubMed ID: 19254207 [TBL] [Abstract][Full Text] [Related]
6. Non-nucleoside inhibitors of herpesviruses. Wathen MW Rev Med Virol; 2002; 12(3):167-78. PubMed ID: 11987142 [TBL] [Abstract][Full Text] [Related]
7. 2-deoxy-D-glucose as a potential drug against fusogenic viruses including HIV. Parris GE Med Hypotheses; 2008; 70(4):776-82. PubMed ID: 17920779 [TBL] [Abstract][Full Text] [Related]
8. Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia. Jancel T; Penzak SR Semin Hematol; 2009 Jul; 46(3):230-47. PubMed ID: 19549576 [TBL] [Abstract][Full Text] [Related]
9. New anti-HIV agents and targets. De Clercq E Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088 [TBL] [Abstract][Full Text] [Related]
10. S-nitrosylation of viral proteins: molecular bases for antiviral effect of nitric oxide. Colasanti M; Persichini T; Venturini G; Ascenzi P IUBMB Life; 1999 Jul; 48(1):25-31. PubMed ID: 10791912 [TBL] [Abstract][Full Text] [Related]
14. [Advances in antiviral chemotherapy]. Baba M Uirusu; 2005 Jun; 55(1):69-75. PubMed ID: 16308532 [TBL] [Abstract][Full Text] [Related]
15. Genetic diversity-independent neutralization of pandemic viruses (e.g. HIV), potentially pandemic (e.g. H5N1 strain of influenza) and carcinogenic (e.g. HBV and HCV) viruses and possible agents of bioterrorism (variola) by enveloped virus neutralizing compounds (EVNCs). Kotwal GJ Vaccine; 2008 Jun; 26(24):3055-8. PubMed ID: 18241960 [TBL] [Abstract][Full Text] [Related]
16. The future of antivirals: broad-spectrum inhibitors. Debing Y; Neyts J; Delang L Curr Opin Infect Dis; 2015 Dec; 28(6):596-602. PubMed ID: 26524332 [TBL] [Abstract][Full Text] [Related]
17. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Nijhuis M; van Maarseveen NM; Boucher CA Handb Exp Pharmacol; 2009; (189):299-320. PubMed ID: 19048205 [TBL] [Abstract][Full Text] [Related]
19. [Status and prospects of the chemotherapy of viral infections]. Pershin GN Farmakol Toksikol; 1975; 38(5):517-27. PubMed ID: 1183580 [No Abstract] [Full Text] [Related]
20. Transfer of antivirals across the human placenta. Pacifici GM Early Hum Dev; 2005 Aug; 81(8):647-54. PubMed ID: 15946808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]